Our group and others have reported that the conditioning of immune cells with IL‐2 and TGF-β could represent a therapeutic approach for the restoration of unbalanced immune homeostasis in SLE [reviewed in (6–9)]. Here, TGFB1 is linked to systemic lupus erythematosus.